RPA1 and colorectal carcinoma: The aforementioned therapeutically beneficial targets regulated by μ-21 include both well-characterized protein effectors in CRC, such as MAD2L1, and proteins with limited prior association with CRC pathogenesis, including eIF3F, NPM1, LAMB1, RPL31, and RPA1.